Related Experiment Video

Updated: Jun 11, 2026

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib

A Milano1, F Perri, F Caponigro

  • 1Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy;

Oncotargets and Therapy
|July 10, 2010
PubMed

Insights

Bortezomib, a proteasome inhibitor, shows promise in cancer therapy by inducing cancer cell death. Clinical trials are exploring its effectiveness in solid tumors, building on its success in multiple myeloma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The ubiquitin-proteasome system regulates protein degradation, cell cycle, and apoptosis, making it a key target in cancer therapy.
  • Bortezomib (PS-341) is a reversible proteasome inhibitor with demonstrated in vitro antitumor activity against various hematological and solid malignancies.

Purpose of the Study:

  • To review recent clinical trial data on bortezomib in solid tumors.
  • To highlight bortezomib's mechanism of action and preclinical efficacy.

Main Methods:

  • Review of preclinical studies demonstrating bortezomib's induction of apoptosis via NF-κB inhibition and pro-apoptotic protein stabilization.
  • Summary of in vitro and in vivo data showing bortezomib's ability to sensitize cells to chemotherapy and radiation, and inhibit tumor growth.

Main Results:

  • Bortezomib exhibits potent antitumor activity in preclinical models.
  • The drug has shown efficacy in hematologic malignancies, leading to its approval for multiple myeloma.

Conclusions:

  • Bortezomib is a validated therapeutic target in hematologic cancers.
  • Ongoing clinical trials are evaluating bortezomib's role in treating solid tumors.
Keywords:
NF-κBbortezomibclinical studiesproteasomesolid tumors

More Related Videos

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons09:27

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons

Published on: October 10, 2025

Screening Ion Channels in Cancer Cells06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...